An FDA panel unanimously concluded that the label of Bristol-Myers Squibb's antipsychotic Abilify for use in children lacks information on the risk of excessive weight gain. The panel advised Bristol-Myers to keep monitoring pediatric use of the drug and move data on its metabolic effect on children to the warning section of the label.

Full Story:

Related Summaries